SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 34.72 |
| Enterprise Value ($M) | 20.40 |
| Book Value ($M) | 17.16 |
| Book Value / Share | 0.59 |
| Price / Book | 2.02 |
| NCAV ($M) | 11.59 |
| NCAV / Share | 0.40 |
| Price / NCAV | 3.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.92 |
| Return on Assets (ROA) | -1.75 |
| Return on Equity (ROE) | -5.57 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.61 |
| Current Ratio | 5.61 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 15.28 |
| Assets | 20.85 |
| Liabilities | 3.69 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2.39 |
| Operating Income | -16.52 |
| Net Income | -15.97 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -13.87 |
| Cash from Investing | -0.64 |
| Cash from Financing | 28.79 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | -63.17 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 19,103 | 171,679 | 11.13 | |
| 60,499 | 229,807 | 26.33 | |
| 13,969 | 91,696 | 15.23 | |
| 21,987 | 92,708 | 23.72 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KZR – Kezar Life Sciences, Inc. | LEXX – Lexaria Bioscience Corp. |
| LFVN – LifeVantage Corporation | LIPO – Lipella Pharmaceuticals Inc. |
| LIXT – Lixte Biotechnology Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io